AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Raymond James Trust N.A.

Raymond James Trust N.A. lowered its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 20.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,713 shares of the company's stock after selling 11,239 shares during the quarter. Raymond James Trust N.A.'s holdings in AstraZeneca were worth $3,484,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Stratos Wealth Advisors LLC boosted its stake in shares of AstraZeneca by 2.0% in the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company's stock valued at $522,000 after purchasing an additional 133 shares during the period. Bruce G. Allen Investments LLC grew its stake in shares of AstraZeneca by 19.1% in the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company's stock worth $67,000 after acquiring an additional 138 shares in the last quarter. Carnegie Investment Counsel increased its position in shares of AstraZeneca by 0.8% during the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company's stock worth $1,347,000 after acquiring an additional 138 shares during the period. Crumly & Associates Inc. raised its stake in shares of AstraZeneca by 2.2% in the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company's stock valued at $518,000 after acquiring an additional 143 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its stake in AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company's stock worth $34,000 after purchasing an additional 146 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.

AstraZeneca Stock Performance

Shares of AstraZeneca stock traded up $1.37 on Friday, hitting $65.63. The stock had a trading volume of 7,163,048 shares, compared to its average volume of 8,415,181. The stock has a market cap of $203.49 billion, a price-to-earnings ratio of 31.40, a P/E/G ratio of 1.18 and a beta of 0.47. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company's 50 day moving average price is $73.44 and its 200 day moving average price is $77.79.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analysts' expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm's revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.87 earnings per share. On average, research analysts anticipate that AstraZeneca PLC will post 4.1 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. UBS Group upgraded shares of AstraZeneca from a "sell" rating to a "neutral" rating in a report on Wednesday. TD Cowen increased their target price on AstraZeneca from $90.00 to $95.00 and gave the company a "buy" rating in a report on Monday, August 12th. Erste Group Bank raised AstraZeneca from a "hold" rating to a "buy" rating in a report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised AstraZeneca from a "sell" rating to a "hold" rating in a research report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.